SCHEMBL960190

SCHEMBL960190

C[C]1CC(C)C1(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3103528 0.71
SCHEMBL9250222 0.67
SCHEMBL3819690 0.67
SCHEMBL6129665 0.67
SCHEMBL2693191 0.67
SCHEMBL5365813 0.66 CA1 (0.34)
SCHEMBL9284434 0.66
SCHEMBL3121804 0.63
SCHEMBL11683344 0.63 ALDH1A1 (0.31)
SCHEMBL15657312 0.63 CRBN (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240131023-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2024-04-25 US claimed
CN-115175901-A Compounds and methods for targeted degradation of androgen receptor 阿尔维纳斯运营股份有限公司 2022-10-11 CN claimed
US-20210196710-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2021-07-01 US claimed
WO-2021127443-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. (US) 2021-06-24 WO claimed
US-20240180900-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2024-06-06 US disclosed
WO-2024091975-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. (US) 2024-05-02 WO disclosed
US-20240131023-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2024-04-25 US disclosed
US-11883393-B2 Compounds and methods for the targeted degradation of androgen receptor ARVINAS OPERATIONS, INC. (US) 2024-01-30 US disclosed
EP-4045095-B1 IRON (III) COMPLEXES WITH NOVEL CONTRAST PROPERTIES FOR MAGNETIC RESONANCE IMAGING UNIV BERLIN CHARITE (DE) 2023-08-02 EP disclosed
CN-115175901-A Compounds and methods for targeted degradation of androgen receptor 阿尔维纳斯运营股份有限公司 2022-10-11 CN disclosed
US-20210196710-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. 2021-07-01 US disclosed
WO-2021127443-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR ARVINAS OPERATIONS, INC. (US) 2021-06-24 WO disclosed
US-20120167949-A1 METHOD OF ENHANCING IRRADIANCE PROFILE FROM SOLAR CONCENTRATOR COOLEARTH SOLAR (US) 2012-07-05 US disclosed
WO-2012092398-A1 METHOD OF ENHANCING IRRADIANCE PROFILE FROM SOLAR CONCENTRATOR COOLEARTH SOLAR (US) 2012-07-05 WO disclosed
US-20110092700-A1 Novel Coumarin Derivative Having Antitumor Activity IIKURA HITOSHI 2011-04-21 US disclosed
US-7897792-B2 Coumarin derivative having antitumor activity CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-03-01 US disclosed
US-20110009398-A1 p27 Protein Inducer CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-01-13 US disclosed
EP-2172198-A1 p27 PROTEIN INDUCER Chugai Seiyaku Kabushiki Kaisha (JP) 2010-04-07 EP disclosed
US-20100004233-A1 NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-01-07 US disclosed
EP-1982982-A1 NOVEL COUMARIN DERIVATIVE HAVING ANTITUMOR ACTIVITY CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-10-22 EP disclosed